Adding Toripalimab to Chemotherapy Improves Survival in Advanced NSCLC
Adding toripalimab to first-line chemotherapy improves overall survival in patients with advanced non-small cell lung cancer, a phase 3 study suggests.
Adding toripalimab to first-line chemotherapy improves overall survival in patients with advanced non-small cell lung cancer, a phase 3 study suggests.
Chemotherapy is more effective than toripalimab as adjuvant therapy in patients with resected mucosal melanoma, a study suggests.
Adding nimorazole to radiotherapy does not improve outcomes in patients with locally advanced head and neck cancer who have tumor hypoxia, phase 3 data suggest.
Adding talazoparib to atezolizumab maintenance can improve progression-free survival in patients with SLFN11+ extensive-stage small cell lung cancer, a phase 2 trial suggests.
Adding elotuzumab to carfilzomib, lenalidomide, and dexamethasone leads to deeper remissions in transplant-eligible, newly diagnosed multiple myeloma, data suggest.
Zanidatamab can produce rapid and durable responses in patients with advanced HER2-positive biliary tract cancer, phase 2 data suggest.
Serious mental illness is associated with longer hospital stays among patients undergoing lung cancer resection, according to a new study.
The association between disease progression and PD-1/PD-L1 inhibitors in non-small cell lung cancer is unknown.
Patients with severe complications, such as interstitial lung disease, are often excluded from clinical studies assessing chemotherapy in NSCLC.
Previous studies showed that elotuzumab plus lenalidomide and dexamethasone improved progression-free survival and response rates, but its impact on patient-reported outcomes is unknown.